True Health Technology (HKG:2697) said it has completed animal testing of its organ support machine involving gene-edited pig livers and primates with acute liver failure, according to a Monday bourse filing.
The company said early results showed stable physiological parameters in the subjects, with no hyperacute or acute rejections.
Shares were last down 4.3% in Tuesday afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments